Cancer Letters
Volume 275, Issue 1 , Pages 17-26 , 8 March 2009

Myricetin directly targets JAK1 to inhibit cell transformation

Received 18 June 2008 ,Revised 2 September 2008 ,Accepted 30 September 2008.

References 

  1. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004;18:8017–8023
  2. Darnell JE. STATs and gene regulation. Science. 1997;12:1630–1635
  3. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets. 2006;6:107–121
  4. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 2004;1:2382–2389
  5. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 2004;114:720–728
  6. Yamaoka K, Saharinen P, Pesu M, Holt VE, Silvennoinen O, O’Shea JJ. The Janus kinases. Genome Biol. 2004;253:
  7. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19:5662–5679
  8. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;27:6613–6626
  9. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta. 2006;1766:120–139
  10. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005;1:0010
  11. Lin J, Zhang SM, Wu K, Willett WC, Fuchs CS, Giovannucci E. Flavonoid intake and colorectal cancer risk in men and women. Am. J. Epidemiol. 2006;1:644–651
  12. Ong KC, Khoo HE. Biological effects of myricetin. Gen. Pharmacol. 1997;29:121–126
  13. Ko CH, Shen SC, Hsu CS, Chen YC. Mitochondrial-dependent, reactive oxygen species-independent apoptosis by myricetin: roles of protein kinase C, cytochrome c, and caspase cascade. roles of protein kinase C, cytochrome c, and caspase cascade. Biochem. Pharmacol. 2005;15:913–927
  14. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 2006;15:4410–4418
  15. Ko CH, Shen SC, Lee TJ, Chen YC. Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol. Cancer Ther. 2005;4:281–290
  16. Ichimatsu D, Nomura M, Nakamura S, Moritani S, Yokogawa K, Kobayashi S, et al. Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells. Mol. Carcinog. 2007;46:436–445
  17. Lee KM, Kang NJ, Han JH, Lee KW, Lee HJ. Myricetin down-regulates phorbol ester-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking activation of nuclear factor kappa B. J. Agric. Food Chem. 2007;14:9678–9684
  18. Liu IM, Tzeng TF, Liou SS, Lan TW. Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats. Life Sci. 2007;10:1479–1488
  19. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 2007;28:1918–1927
  20. Hou DX, Kai K, Li JJ, Lin S, Terahara N, Wakamatsu M, et al. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure–activity relationship and molecular mechanisms. Carcinogenesis. 2004;25:29–36
  21. Tanigawa S, Fujii M, Hou DX. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 2007;1:1690–1703
  22. Kamihira M, Nakazawa H, Kira A, Mizutani Y, Nakamura M, Nakayama T. Interaction of tea catechins with lipid bilayers investigated by a quartz-crystal microbalance analysis. Biosci. Biotechnol. Biochem. 2008;72:1372–1375
  23. Cen X, Nitta A, Ohya S, Zhao Y, Ozawa N, Mouri A, et al. An analog of a dipeptide-like structure of FK506 increases glial cell line-derived neurotrophic factor expression through cAMP response element-binding protein activated by heat shock protein 90/Akt signaling pathway. J. Neurosci. 2006;26:3335–3344
  24. Sato Y, Sagami I, Shimizu T. Identification of caveolin-1-interacting in neuronal nitric-oxide synthase. J. Biol. Chem. 2004;279:8827–8836
  25. Lim CP, Cao X. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem. 1999;274:31055–31061
  26. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 2006;66:8511–8519
  27. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 2002;4:774–778
  28. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 2003;9:316–326
  29. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-kB and Pdcd4. Trends Mol. Med. 2003;9:36–41
  30. Ermakova S, Choi BY, Choi HS, Kang BS, Bode AM, Dong Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J. Biol. Chem. 2005;280:16882–16890
  31. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, et al. (−)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006;66:9260–9269
  32. Li M, He Z, Ermakova S, Zheng D, Tang F, Cho YY, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomark. Prev. 2007;16:598–605
  33. Kang NJ, Lee KW, Rogozin EA, Cho YY, Heo YS, Bode AM, et al. Equal, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J. Biol. Chem. 2007;282:32856–32866
  34. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 2008;68:946–955
  35. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, et al. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog. 2008;47:797–805
  36. Kang NJ, Lee KW, Lee DE, Rogozin EA, Bode AM, Lee HJ, et al. Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase. J. Biol. Chem. 2008;283:20664–20673
  37. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003;284:31–53
  38. Kil SJ, Carlin C. EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand–receptor complexes in early endosomal compartments. J. Cell. Physiol. 2000;185:47–60
  39. Thien CB, Walker F, Langdon WY. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol. Cell. 2001;7:355–365

PII: S0304-3835(08)00797-0

doi: 10.1016/j.canlet.2008.09.027

Cancer Letters
Volume 275, Issue 1 , Pages 17-26 , 8 March 2009

Article Tools

* Image Usage & Resolution